Home Cart Sign in  
Chemical Structure| 1953133-47-5 Chemical Structure| 1953133-47-5

Structure of Giredestrant
CAS No.: 1953133-47-5

Chemical Structure| 1953133-47-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Giredestrant (GDC-9545), a non-steroidal ER ligand, is an orally active and selective estrogen receptor (ER) antagonist. Giredestrant potently competes with estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity[1].

Synonyms: GDC-9545; RG6171

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Giredestrant

CAS No. :1953133-47-5
Formula : C27H31F5N4O
M.W : 522.55
SMILES Code : OCC(F)(F)CN([C@@H]1C2=C(F)C=C(NC3CN(CCCF)C3)C=C2F)[C@H](C)CC4=C1NC5=C4C=CC=C5
Synonyms :
GDC-9545; RG6171
MDL No. :MFCD32710075

Safety of Giredestrant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05634499 Endometrial Cancer PHASE2 ACTIVE_NOT_RECRUITING 2025-12-31 University of Arkansas for Med... More >>ical Sciences, Little Rock, Arkansas, 72205, United States|Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States|Minnesota Oncology Minneapolis, Minneapolis, Minnesota, 55404, United States|Englewood Health/Hematology Oncology Practice of Englewood (HOPE), Englewood, New Jersey, 07631, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, 15224, United States|Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas, 76104, United States|Virginia Oncology Associates, Norfolk, Virginia, 23502, United States|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, H4A 3J1, Canada|Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS, Meldola, Emilia-Romagna, 47014, Italy|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice, Gliwice, 44-101, Poland|Swietokrzyskie Centrum Onkologii, Kielce, 25-734, Poland Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.57mL

1.91mL

0.96mL

19.14mL

3.83mL

1.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories